OS Therapies (OSTX) Competitors

$3.52

-0.01 (-0.28%)

(As of 09/18/2024 ET)

OSTX vs. QURE, ACRV, SCPH, MGTX, CDXC, ENTA, SOPH, MRSN, ADCT, and ELYM

Should you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include uniQure (QURE), Acrivon Therapeutics (ACRV), scPharmaceuticals (SCPH), MeiraGTx (MGTX), ChromaDex (CDXC), Enanta Pharmaceuticals (ENTA), SOPHiA GENETICS (SOPH), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.

OS Therapies vs.

uniQure (NASDAQ:QURE) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.

: In the previous week, OS Therapies had 2 more articles in the media than uniQure. MarketBeat recorded 2 mentions for OS Therapies and 0 mentions for uniQure. uniQure's average media sentiment score of 1.89 beat OS Therapies' score of 0.33 indicating that uniQure is being referred to more favorably in the media.
Company Overall Sentiment
uniQure Very Positive
OS Therapies Neutral
: OS Therapies has a net margin of 0.00% compared to uniQure's net margin of -1,027.52%. OS Therapies' return on equity of 0.00% beat uniQure's return on equity.
Company Net Margins Return on Equity Return on Assets
uniQure -1,027.52% -158.09% -35.54%
OS Therapies N/A N/A N/A
: uniQure received 638 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 70.64% of users gave uniQure an outperform vote.
Company Underperform Outperform
uniQure Outperform Votes
640
70.64%
Underperform Votes
266
29.36%
OS Therapies Outperform Votes
2
100.00%
Underperform Votes
No Votes
: uniQure presently has a consensus target price of $18.60, indicating a potential upside of 222.92%. Given uniQure's higher possible upside, equities research analysts plainly believe uniQure is more favorable than OS Therapies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
0 Sell rating(s)
2 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.60
OS Therapies
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
4.00
: 78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: OS Therapies has lower revenue, but higher earnings than uniQure.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
uniQure $27.71M 10.09 -$308.48M -$6.21 -0.93
OS Therapies N/A N/A N/A N/A N/A

Company	Overall Sentiment
uniQure	Very Positive
OS Therapies	Neutral

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,027.52%	-158.09%	-35.54%
OS Therapies	N/A	N/A	N/A

Company	Underperform	Outperform
uniQure	Outperform Votes 640 70.64%	Underperform Votes 266 29.36%
OS Therapies	Outperform Votes 2 100.00%	Underperform Votes No Votes

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
OS Therapies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	4.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$27.71M	10.09	-$308.48M	-$6.21	-0.93
OS Therapies	N/A	N/A	N/A	N/A	N/A

Summary

uniQure and OS Therapies tied by winning 7 of the 14 factors compared between the two stocks.

Ad Golden Crest

Biden's Successor: The Radical Threat to YOUR Savings!

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

Get OS Therapies News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OSTX vs. The Competition

Export to Excel

Metric	OS Therapies	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$70.58M	$7.86B	$5.67B	$18.99B
Dividend Yield	N/A	4.33%	4.99%	3.54%
P/E Ratio	N/A	19.61	140.32	26.31
Price / Sales	N/A	238.85	1,617.68	14.56
Price / Cash	N/A	37.11	37.21	19.90
Price / Book	N/A	5.87	4.82	5.06
Net Income	N/A	$151.12M	$115.60M	$982.71M
7 Day Performance	0.28%	4.05%	3.72%	3.34%
1 Month Performance	1.15%	12.35%	8.86%	2.87%
1 Year Performance	N/A	21.73%	28.72%	19.64%

OS Therapies Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.863 of 5 stars 2.86 / 5 stars	$5.66 +2.2%	$18.60 +228.6%	-29.0%	$275.64M	$15.84M	-0.91	500	Positive News
ACRV Acrivon Therapeutics	2.6091 of 5 stars 2.61 / 5 stars	$8.91 -3.6%	$23.14 +159.7%	-28.0%	$275.11M	N/A	-3.09	58	Analyst Upgrade News Coverage
SCPH scPharmaceuticals	3.8779 of 5 stars 3.88 / 5 stars	$5.49 +3.4%	$18.00 +227.9%	-21.5%	$274.67M	$13.59M	-3.71	30	Positive News
MGTX MeiraGTx	4.4427 of 5 stars 4.44 / 5 stars	$4.25 +1.9%	$22.50 +429.4%	-24.8%	$273.31M	$8.12M	-3.63	300	Gap Down
CDXC ChromaDex	4.4919 of 5 stars 4.49 / 5 stars	$3.55 +1.4%	$6.00 +69.0%	+132.0%	$269.55M	$83.57M	-71.00	120
ENTA Enanta Pharmaceuticals	4.2573 of 5 stars 4.26 / 5 stars	$12.43 +2.0%	$19.00 +52.9%	-8.5%	$263.39M	$79.20M	-1.99	160	News Coverage Positive News
SOPH SOPHiA GENETICS	2.2307 of 5 stars 2.23 / 5 stars	$4.01 +2.8%	$6.50 +62.1%	+65.1%	$262.15M	$64.94M	-3.58	520	Gap Down
MRSN Mersana Therapeutics	4.2226 of 5 stars 4.22 / 5 stars	$2.11 +19.2%	$6.00 +184.4%	+43.7%	$258.86M	$36.85M	-1.85	150	Short Interest ↑ Gap Up
ADCT ADC Therapeutics	3.2841 of 5 stars 3.28 / 5 stars	$3.10 +5.4%	$9.00 +190.3%	+281.1%	$256.61M	$66.75M	-1.13	310	Short Interest ↓
ELYM Eliem Therapeutics	0.6036 of 5 stars 0.60 / 5 stars	$8.46 +5.8%	N/A	+193.7%	$251.70M	N/A	-15.96	20	Short Interest ↑